Post operative infection and increased survival in osteosarcoma patients: are they associated? - PubMed (original) (raw)
. 2007 Oct;14(10):2887-95.
doi: 10.1245/s10434-007-9483-8. Epub 2007 Jul 26.
Affiliations
- PMID: 17653803
- DOI: 10.1245/s10434-007-9483-8
Post operative infection and increased survival in osteosarcoma patients: are they associated?
L M Jeys et al. Ann Surg Oncol. 2007 Oct.
Abstract
Background: Despite neo-adjuvant chemotherapy osteosarcomas having significant mortality, recent studies have shown survival advantages following infections for some tumour types. This study investigates the effect of post-operative infection in patients treated for osteosarcoma using endoprosthetic replacement and neo-adjuvant chemotherapy.
Material and methods: A consecutive series of 547 patients underwent surgery between 1981 and 2001 for osteosarcoma. Patients were excluded from the study if over 60 years old at diagnosis (n = 14) as they would not routinely receive chemotherapy. Studies showed that 70% of deep infections occur within one year from reconstruction. Therefore landmark analysis was performed; all patients infected after 12 months of reconstruction were excluded (15 patients, 2.7%) and those who died within 12 months from diagnosis due to metastases were excluded (105 patients, 19.2%), leaving 412 patients. Any survival advantage of early infection was analysed by Kaplan-Meier survival analysis from this landmark point.
Results: Overall population survival was 65% at 10 years after landmarking. There were 41 patients (10%) who developed an infection within one year of implantation. These patients had significantly better survival (p = 0.017). The 10-year survival for patients with osteosarcoma with infection was 84.5% compared to 62.3% in the non-infected group after landmarking. There was no significant difference in the percentage post-chemotherapy specimen necrosis between the two groups (p = 0.36). Infection was an independent prognostic factor on cox regression analysis.
Conclusions: There was evidence for increased survival after deep post-operative infection in osteosarcoma patients, in keeping with other research. The authors feel this warrants further investigation.
Similar articles
- Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS; Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Kager L, et al. J Clin Oncol. 2003 May 15;21(10):2011-8. doi: 10.1200/JCO.2003.08.132. J Clin Oncol. 2003. PMID: 12743156 - Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma.
Lascelles BD, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC, Withrow SJ. Lascelles BD, et al. Ann Surg Oncol. 2005 Dec;12(12):1073-83. doi: 10.1245/ASO.2005.01.011. Epub 2005 Oct 28. Ann Surg Oncol. 2005. PMID: 16252138 - Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K. Kempf-Bielack B, et al. J Clin Oncol. 2005 Jan 20;23(3):559-68. doi: 10.1200/JCO.2005.04.063. J Clin Oncol. 2005. PMID: 15659502 - [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N, Alkallaf S, Cornille H, Markowska B, Delépine G. Delépine N, et al. Ann Med Interne (Paris). 2003 Feb;154(1):12-24. Ann Med Interne (Paris). 2003. PMID: 12746655 Review. French. - "Osteosarcoma". A review of the management used and results in 28 patients.
Abdelnoor J, Kourani N, Semaan T. Abdelnoor J, et al. J Med Liban. 1992;40(4):190-3. J Med Liban. 1992. PMID: 1339905 Review.
Cited by
- Postoperative infection and bone sarcoma survival: systematic review of the role of infection in bone sarcoma prognosis.
Dooley SW, Gong MF, Carlson LA, Frear AJ, Mandell JB, Zheng A, Bhogal S, Schoedel KE, Weiss KR. Dooley SW, et al. Ann Jt. 2023 Jun 29;8:22. doi: 10.21037/aoj-22-41. eCollection 2023. Ann Jt. 2023. PMID: 38529233 Free PMC article. Review. - A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.
Richert I, Berchard P, Abbes L, Novikov A, Chettab K, Vandermoeten A, Dumontet C, Karanian M, Kerzerho J, Caroff M, Blay JY, Dutour A. Richert I, et al. Cancers (Basel). 2023 Sep 19;15(18):4635. doi: 10.3390/cancers15184635. Cancers (Basel). 2023. PMID: 37760603 Free PMC article. - Infections of Tumor Prostheses: An Updated Review on Risk Factors, Microbiology, Diagnosis, and Treatment Strategies.
Tsantes AG, Altsitzioglou P, Papadopoulos DV, Lorenzo D, Romanò CL, Benzakour T, Tsukamoto S, Errani C, Angelini A, Mavrogenis AF. Tsantes AG, et al. Biology (Basel). 2023 Feb 15;12(2):314. doi: 10.3390/biology12020314. Biology (Basel). 2023. PMID: 36829589 Free PMC article. Review. - Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.
Hattinger CM, Salaroglio IC, Fantoni L, Godel M, Casotti C, Kopecka J, Scotlandi K, Ibrahim T, Riganti C, Serra M. Hattinger CM, et al. Int J Mol Sci. 2023 Jan 2;24(1):799. doi: 10.3390/ijms24010799. Int J Mol Sci. 2023. PMID: 36614241 Free PMC article. Review. - Improving Osteosarcoma Treatment: Comparative Oncology in Action.
Tarone L, Mareschi K, Tirtei E, Giacobino D, Camerino M, Buracco P, Morello E, Cavallo F, Riccardo F. Tarone L, et al. Life (Basel). 2022 Dec 14;12(12):2099. doi: 10.3390/life12122099. Life (Basel). 2022. PMID: 36556464 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical